LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws,
Chief Financial Officer, will be leaving the company in early June 2017
to return to investment banking. He will be joining Baird as Managing
Director in the firm's Life Sciences and Biotechnology Group. Mr. Daws
will continue to consult with the Company, including through the closing
of the pending asset purchase agreement with Vertex Pharmaceuticals,
Inc. Mr. Daws served as CFO of Concert since January 2014. Concert has
initiated a search to appoint a new CFO.
"We are grateful for Ryan's contributions over the last several years.
He has played an important role within the Company including in our
finance, investor relations and business development activities. Most
notably, Ryan was instrumental in the CTP-656 asset purchase agreement
with Vertex, which upon closing will significantly extend our cash
runway," said Roger Tung, Ph.D. President and Chief Executive Officer of
Concert. "We greatly appreciate all he has done and wish him continued
success in the future."
"I am confident that Concert's DCE Platform will continue to result in
important, new medicines to address unmet needs of patients," said Mr.
Daws, Chief Financial Officer of Concert. "It has been a privilege to be
part of the Concert team and I look forward to supporting the Company as
we work to close the Vertex transaction."
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, autoimmune and inflammatory diseases and
central nervous systems (CNS) disorders. For more information please
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005350/en/
Concert Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media